Apellis Pharmaceuticals Inc(APLS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 41.01 | EPS (ttm) | 1 | Insider Own | 30.77% | Shs Outstand | 127.9M | Perf Week | - |
| Market Cap | 5.25B | Forward P/E | - | EPS next Y | 74.86% | Insider Trans | -0.31% | Shs Float | 88.6M | Perf Month | 0.1% |
| Enterprise Value | 5.32B | PEG | - | EPS next Q | -0.24 | Inst Own | 110.31% | Short Float | 12.13% | Perf Quarter | 89.6% |
| Income | 0.13B | P/S | 4.75 | EPS this Y | -665% | Inst Trans | -9.08% | Short Ratio | 1.68 | Perf Half Y | 103.83% |
| Sales | 1.11B | P/B | 12.65 | EPS next 5Y | 53.35% | ROA | 14.1% | Short Interest | 10.75M | Perf YTD | 63.34% |
| Book/sh | 3.24 | P/C | 12.91 | EPS past 3/5Y | - | ROE | 46.02% | 52W High | -0.27% ($41.14) | Perf Year | 137.44% |
| Cash/sh | 3.18 | P/FCF | 140.18 | Sales past 3/5Y | 136.98% 31.98% | ROIC | 16.87% | 52W Low | 154.84% ($16.10) | Perf 3Y | -53.35% |
| Dividend Est. | - | EV/EBITDA | 31.94 | EPS Y/Y TTM | 158.69% | Gross Margin | 90.09% | Volatility(W/M) | 0.13% 0.15% | Perf 5Y | -10.1% |
| Dividend TTM | - | EV/Sales | 4.81 | Sales Y/Y TTM | 42.46% | Oper. Margin | 14.95% | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.16 | EPS Q/Q | 119.32% | Profit Margin | 12.06% | RSI (14) | 84.48 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.63 | Sales Q/Q | 60.85% | SMA20 | 0.14% ($40.97) | Beta | -0.25 | Target Price | $41 |
| Payout | - | Debt/Eq | 1.15 | Earnings | 2026/2/24 | SMA50 | 26.8% ($32.36) | Rel Volume | 0 | Prev Close | $41.03 |
| Employees | 739 | LT Debt/Eq | 0.9 | EPS/Sales Surpr. | -25.67% 0.26% | SMA200 | 58.68% ($25.86) | Avg Volume(3M) | 6.42M | Price | $41.03 |
| IPO | 2017/11/9 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
A commercial-stage biotech company that develops and markets therapeutics targeting the complement pathway of the immune system. It sells an ophthalmic injection for age-related retinal diseases and treatments for rare blood and kidney disorders. As a healthcare stock, its value is driven by core therapeutic revenue, label expansions, and the competitive landscape.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
APLS makes money exceptionally well
Of every $100 in sales, $14.95 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -665.0% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $4,101. Peers typically go for $4,608.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -10.1%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 110.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #45 of 599 in the industry
Based on market cap of $5B.
FAQ
APLS belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of APLS is approximately $5.3B, ranking 1,352 within its sector.
APLS has a P/E ratio of approximately 41.0x, which can be used to assess its valuation relative to the Healthcare sector average.
APLS has recorded a 52-week high of $41.14 and a low of $16.10.